Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Correspondence] Should hydroxyethyl starch be banned? – Authors’ reply

Medicines should be licensed for use when there is reliable evidence that patients benefit from them. In their Correspondences, Michael Frank James and colleagues and Hans-Joachim Priebe overlook this crucial point. Instead, they cast doubt on the high-quality randomised trials that question the safety of hydroxyethyl starch (HES), or claim that future studies might show some benefit for its use. They wrongly assert that CHEST trial data are being withheld when these are probably the only fluid trial data that have been independently reanalysed (confirming the integrity of the analysis and conclusions), and which remain available for further analysis in accordance with the sponsor’s open data policy.